Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Swain SM, Kim SB, Cort├ęs J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J.

Lancet Oncol. 2013 May;14(6):461-71. doi: 10.1016/S1470-2045(13)70130-X. Epub 2013 Apr 18.

PMID:
23602601
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.

Keating GM.

Drugs. 2012 Feb 12;72(3):353-60. doi: 10.2165/11209000-000000000-00000. Review.

PMID:
22316351
[PubMed - indexed for MEDLINE]
3.

Current and future anti-HER2 therapy in breast cancer.

Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.

J BUON. 2013 Jan-Mar;18(1):4-16. Review.

PMID:
23613383
[PubMed - indexed for MEDLINE]
4.

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Review.

PMID:
22953713
[PubMed - indexed for MEDLINE]
5.

HER2-directed therapy for metastatic breast cancer.

Jelovac D, Emens LA.

Oncology (Williston Park). 2013 Mar;27(3):166-75. Review.

PMID:
23687784
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk